Advertisement · 728 × 90
#
Hashtag
#JN1
Advertisement · 728 × 90
Post image

Scientists develop a #RBDXBB15HR #vaccine inducing strong humoral and #CellularImmunity, boosting neutralization against #JN1 and #XBB subvariants, and showing protection against live #Omicron viruses—advancing next-gen #COVID19 vaccine strategies.

#STTT: doi.org/10.1038/s413...

0 0 0 0

#JN1 ist dann quasi der „alte“ Impfstoff aus dem Vorjahr neu aufgelegt, oder?

3 0 1 0
Preview
Covid-19: Health Ministry urges high-risk groups to get vaccinated amid JN.1 subvariant spread KUCHING, June 12 —The Ministry of Health (MoH) has assured the public that the JN.1 Covid-19 subvariant, which has been spreading recently, is not as dangerous as the variants...

#Malaysia, #Covid19: Health Ministry urges high-risk groups to get vaccinated amid #JN1 #subvariant spread www.malaymail.com/news/malaysi...

1 0 0 0

Wo findet mensch eine Übersicht über die derzeit in Deutschland kursierenden #SarsCoV2-#Varianten, deren Verteilung und Wachstum?

Ich versuche mich der Entscheidung zu nähern, ob es angesichts der Entwicklung lohnt, auf angepasste Impfstoffe zu warten oder bald nochmals #JN1 Nuvaxovid zu nehmen.

21 10 1 0

Feverʼs pretty much gone. Inanahi was pretty miserable. Still, better than getting the plague. #COVID19 #JN1 #vaccination

0 0 0 0

Second Ibuprofen dose. Glad I stocked up on this in Sweden last summer. Definitely more feverish with the #JN1 vaccine. #COVID19

0 0 0 0

Numb arm and fever, but better than getting the actual thing! #COVID19 #JN1 #vaccination

0 0 0 0

Shot bro. #COVID19 #JN1 #vaccination

0 0 0 0

Ich hatte Ende September 24 #COVID19 - Nachdem ich im August direkt die #BoosterImpfung mit #BioNTech #JN1 erhalten hatte.

Unter Berücksichtigung der Impfung im August, der Infektion Ende September und der aktuell niedrigen Fallzahlen - Wann macht eine Boosterimpfung wieder Sinn? 🤔

#TeamVorsicht

12 2 4 0
Kind mit Zöpfen trägt eine Atemschutzmaske.   In der rechten Hand hält das Kind einen Teddybären und mit der linken Hand wehrt das Kind zwei wütende Corona-Viren ab.   Auf dem linken Oberarm klebt ein Impfpflaster.   Der Schatten des Kindes reckt das Kind in einer Kraftpose die Arme angewinkelt in die Höhe.

Kind mit Zöpfen trägt eine Atemschutzmaske. In der rechten Hand hält das Kind einen Teddybären und mit der linken Hand wehrt das Kind zwei wütende Corona-Viren ab. Auf dem linken Oberarm klebt ein Impfpflaster. Der Schatten des Kindes reckt das Kind in einer Kraftpose die Arme angewinkelt in die Höhe.

Impfaktion am 18.1. 2025 in #berlinmitte

#Comirnaty #JN1 (Alter ab 6 Monate)
und
#Novavax #Nuvaxovid #JN1 (ab 12 Jahren).

Kosten: 15€/Impfling.

Für Voranmeldung Mail-Adresse bei uns erfragen.

👉 Impfung@bildungabersicher.net👈

#BildungAberSicher
#ImpfenSchützt

70 32 1 2

My experience #JN1vaccine in Melbourne
1. chemist, it was XBB not #jn1 they were ready to give us. 2. GP app.- latest/Pfizer…good, bla, bla, no #jn1
3. new chemist: bad paperwork by 1st chemist, undoing that… then my partner receives jn1 😄 👏
I have to wait till next year, over 64 but not yet 75.

1 0 0 0

#JN1 #ATAGI #COVIDwaves #bosters #JN1Vaccine #covidisnotoverAustralia

1 0 0 0

I also booked for #jn1 at Terry White pharmacy in Melbourne today and almost received the old one. Then I was made to understand that it was a misunderstanding & that they haven’t been aware of the fact that jn1 can be now ordered. #covidaus #aushealth

4 0 1 0
box of pfizer comirnaty jn1 covid vaccine

box of pfizer comirnaty jn1 covid vaccine

since I saw a post saying they'd booked a #jn1 #covid booster and actually received an old XBB.1.5 from a pharmacy clearing out old stock - for #brisbane people, Morningside family medical centre definitely seem to be giving out the jn.1 shot

3 0 0 1
Image of JN1 Covid vaccine booster booking availability at some Terry White chemists in Sydney.

Image of JN1 Covid vaccine booster booking availability at some Terry White chemists in Sydney.

For anyone in #Sydney wanting the *latest* #JN1 #Covid booster, it’s now available in some pharmacies. Yet to arrive in many regional NSW areas ⏰🐌

#covidaware #covidsafe

4 0 1 0

Folgendes Szenario: Donnerstags Booster geimpft, Montag drauf positiver Schnelltest ... abgesehen davon, dass die Person sich wahrscheinlich trotz Maske beim Impftermin angesteckt hat, weil einzige dort mit Maske - hat die #Impfung irgendeinen Wert, oder ist quasi verpufft? #CovidIsNotOver #JN1 #KP2

0 1 0 0

kbv.de/html/1150_7297….

#TeamVorsicht Der #JN1 #Impfstoff #Nuvaxovid von #Novavax kann ab sofort für Lieferung für die Woche 16.12.24 bestellt werden. Er kommt in Einzeldosis-Fläschchen. #ImpfenSchützt #Corona #LongCovid

1 0 0 0
Figure: Cell entry and neutralisation escape by SARS-CoV-2 variants KP.3.1.1 and XEC.

(E) Neutralisation sensitivity of pseudovirus particles bearing JN.1, KP.3.1.1, or XEC S proteins.
Two cohorts were analysed: cohort 1 = 33 individuals, sampling was performed before and 21 day
after JN.1 booster vaccination; cohort 2 = 14 individuals with recent SARS-CoV-2 infection in the
summer of 2024. Pseudovirus particles bearing the indicated S proteins were preincubated with plasma dilutions before being inoculated onto Vero cells. Relative inhibition of pseudovirus entry
was calculated using particles incubated in the absence of plasma as control (= 0% inhibition).
Individual NT50 (neutralizing titre 50) values were determined for each plasma using a non-linear
regression model and geometric mean titres (GMT) were calculated for the respective sample groups. The lowest plasma dilution tested (dashed lines) and the threshold (lower limit of detection, LLOD; grey shaded areas) are indicated. Samples that yielded NTSO values below 12-5 (LLOD) were considered negative and manually assigned a value of 1. Presented are the GMTs (indicated by horizontal black lines and numerical values), response rates and fold changes in neutralisation compared to JN.1pp. Data were derived from a single experiment, performed with four technical replicates. Please also see Supplementary Information Figure S3, S4 and S5 for more information.
(F) The donor-matched neutralisation data for cohort 1 before and 21 days after JN.1 booster vaccination are shown (lines connect pre- and post-booster samples from the same plasma donors).
Information above the graphs indicate GMTs and the mean fold change in neutralisation between
pre- and post-booster samples. Statistical significance was assessed by Wilcoxon matched-pairs signed rank test (p ≤ 0.0001; ****). Please also see Supplementary Information Figure S3, S4 and S5 for more information.

Figure: Cell entry and neutralisation escape by SARS-CoV-2 variants KP.3.1.1 and XEC. (E) Neutralisation sensitivity of pseudovirus particles bearing JN.1, KP.3.1.1, or XEC S proteins. Two cohorts were analysed: cohort 1 = 33 individuals, sampling was performed before and 21 day after JN.1 booster vaccination; cohort 2 = 14 individuals with recent SARS-CoV-2 infection in the summer of 2024. Pseudovirus particles bearing the indicated S proteins were preincubated with plasma dilutions before being inoculated onto Vero cells. Relative inhibition of pseudovirus entry was calculated using particles incubated in the absence of plasma as control (= 0% inhibition). Individual NT50 (neutralizing titre 50) values were determined for each plasma using a non-linear regression model and geometric mean titres (GMT) were calculated for the respective sample groups. The lowest plasma dilution tested (dashed lines) and the threshold (lower limit of detection, LLOD; grey shaded areas) are indicated. Samples that yielded NTSO values below 12-5 (LLOD) were considered negative and manually assigned a value of 1. Presented are the GMTs (indicated by horizontal black lines and numerical values), response rates and fold changes in neutralisation compared to JN.1pp. Data were derived from a single experiment, performed with four technical replicates. Please also see Supplementary Information Figure S3, S4 and S5 for more information. (F) The donor-matched neutralisation data for cohort 1 before and 21 days after JN.1 booster vaccination are shown (lines connect pre- and post-booster samples from the same plasma donors). Information above the graphs indicate GMTs and the mean fold change in neutralisation between pre- and post-booster samples. Statistical significance was assessed by Wilcoxon matched-pairs signed rank test (p ≤ 0.0001; ****). Please also see Supplementary Information Figure S3, S4 and S5 for more information.

Auswirkungen der #JN1 -Auffrischungsimpfung auf die Neutralisierung der #SARSCoV2 -Varianten KP.3.1.1 und #XEC

„Wichtig ist, dass die JN.1-Auffrischungsimpfung die Neutralisierung aller getesteten Linien erheblich verbessert hat und daher …

#ImpfenSchuetzt #Booster #VaccinesSaveLives #COVID19

158 57 6 0
Preview
Robust antiviral humoral immunity induced by JN.1 monovalent mRNA vaccines against a broad range of SARS-CoV-2 Omicron subvariants including JN.1, KP.3.1.1 and XEC As of November 2024, SARS-CoV-2 Omicron JN.1 subvariants, such as KP.2 (JN.1.11.1.2), KP.3 (JN.1.11.1.3), KP.3.1.1 (JN.1.11.1.3.1.1), and XEC, a recombinant lineage between KS.1.1 (JN.13.1.1.1) and KP...

Robust antiviral humoral immunity induced by JN.1 monovalent mRNA vaccines against a broad range of SARS-CoV-2 Omicron subvariants, including JN.1, KP.3.1.1 and XEC

#mRNA #Vaccines #XEC #JN1 #KP311
www.biorxiv.org/content/10.1...

0 0 0 0
Preview
MHRA approves adapted Nuvaxovid JN.1 COVID-19 vaccine for adults and children aged 12 plus The Medicines and Healthcare products Regulatory Agency (MHRA) has approved an adapted version of the Nuvaxovid COVID-19 vaccine that targets the Omicron JN.1 COVID-19 subvariant.

👉 “The Medicines and Healthcare products Regulatory Agency (MHRA) has approved an adapted version of the Nuvaxovid COVID-19 vaccine that targets the Omicron JN.1 COVID-19 subvariant.”

Dare I hope?! 🫣 Will they actually let us access it in the UK though?

#Novavax #JN1

www.gov.uk/government/n...

2 0 1 0
Preview
MHRA approves adapted Nuvaxovid JN.1 COVID-19 vaccines for adults and children aged 12 plus The Medicines and Healthcare products Regulatory Agency (MHRA) has approved an adapted version of the Nuvaxovid COVID-19 vaccine that targets the Omicron JN.1 COVID-19 subvariant.

At long last, MHRA has approved Novavax's Nuvaxovid JN.1 in the UK for those aged 12 years and over! How long will it take to become available? #Novavax #JN1
www.gov.uk/government/n...

4 1 1 0

Gerade Info vom PEI erhalten: "Verhandlungen mit #Novavax sind abgeschlossen. ZEPAI steht mit Verbänden der Leistungserbringer in Kontakt & trifft Vorbereitungen. Voraussichtlich Mitte Dezember kann #Nuvaxovid #JN1 verimpft werden. Impfstoff wird in Verpackungen mit je 10 Einzeldosen ausgeliefert".

18 4 1 2
Preview
MHRA approves adapted Nuvaxovid JN.1 COVID-19 vaccines for adults and children aged 12 plus The Medicines and Healthcare products Regulatory Agency (MHRA) has approved an adapted version of the Nuvaxovid COVID-19 vaccine that targets the Omicron JN.1 COVID-19 subvariant.

MHRA have approved Novavax JN.1, for patients aged 12 and over.
It won't be available on the NHS.
How do we get this available on the UK private market, for those who can't have mRNA vaccines? #CovidCautious #CovidAware #Novavax #JN1

www.gov.uk/government/n....

8 4 1 0
Figure 1. Neutralizing antibody responses to the SARS-CoV-2 JN.1 derivatives
(A) Schematic representation of spike (S) protein mutations across SARS-CoV-2
Omicron subvariants. The intensity of the square coloring correlates with mutation frequency. Data were obtained from Outbreak.info (https://outbreak.info/).
(B, C) Neutralizing antibody titers (NT50) against Omicron subvariants in sera from BNT162b2 vaccinees, stratified by prior SARS-CoV-2 infection status: COVID-19-naïve (B, n=14) and previously infected individuals (C, n=5). Brown horizontal bars and numbers represent geometric mean titers. Black numbers indicate fold changes in neutralization resistance relative to XBB. 1.5 (reference strain). The dotted line indicates the limit of detection for this assay.
(D, E) Neutralizing antibody titers against Omicron subvariants measured in two rabbit sera immunized with JN.1 (D) or KP.3 (E) S antigens. Gray cells indicate the immunizing strain (reference). Red and green cells highlight strains showing neutralization resistance and susceptibility, respectively.

Figure 1. Neutralizing antibody responses to the SARS-CoV-2 JN.1 derivatives (A) Schematic representation of spike (S) protein mutations across SARS-CoV-2 Omicron subvariants. The intensity of the square coloring correlates with mutation frequency. Data were obtained from Outbreak.info (https://outbreak.info/). (B, C) Neutralizing antibody titers (NT50) against Omicron subvariants in sera from BNT162b2 vaccinees, stratified by prior SARS-CoV-2 infection status: COVID-19-naïve (B, n=14) and previously infected individuals (C, n=5). Brown horizontal bars and numbers represent geometric mean titers. Black numbers indicate fold changes in neutralization resistance relative to XBB. 1.5 (reference strain). The dotted line indicates the limit of detection for this assay. (D, E) Neutralizing antibody titers against Omicron subvariants measured in two rabbit sera immunized with JN.1 (D) or KP.3 (E) S antigens. Gray cells indicate the immunizing strain (reference). Red and green cells highlight strains showing neutralization resistance and susceptibility, respectively.

Diese Studie zeigt die robuste kreuzneutralisierende Aktivität von Impfstoffen auf JN.1-Basis gegen neu auftretende Varianten, einschließlich der immunflüchtigen Linien KP.3.1.1 & LB.1, und unterstreicht die potenzielle Wirksamkeit von #JN1 -basierten Impfstoffen.

#COVID19 #Corona #ImpfenSchuetzt

143 51 10 3

Voraussichtlich auch #Novavax #Nuvaxovid #JN1, sobald verfügbar ! @drmccoy.bsky.social

5 1 1 0
Preview
Offizielle Website der Stadt Offenbach am Main Wo der Main seinen schönsten Bogen macht, liegt Offenbach. Eine Stadt voller Spannung und auf dem Sprung.

'In #Offenbach hält die Stadt eine Liste von Praxen bereit, die die Impfung anbieten: auf offenbach.de unter dem Menüpunkt „Bürger:innen“ auf „Gesundheit“ und dort auf „Corona-Virus“ klicken.'

#COVID19 #CovidIsNotOver #TeamVorsicht #Impfung #JN1 #Hessen

32 15 1 0

#JN1 Impfsaft drin. 💉🥳

6 0 0 0
Preview
Novavax's Updated 2024-2025 Nuvaxovid™ COVID-19 Vaccine Receives Authorization in the EU - Oct 9, 2024 Novavax, Inc. (Nasdaq: NVAX), a global company advancing protein-based vaccines with its Matrix-M™ adjuvant, today announced that the European Commission granted Marketing Authorization for...

Europäische Kommission erteilt Marktzulassung für den aktualisierten JN.1-Impfstoff von Novavax

ir.novavax.com/press-releas...

#COVID19 #SARSCoV2 #JN1 #Coronavirus #CovidIsNotOver #ImpfenSchuetzt #LongCovid #Novavax

70 30 3 2
Preview
Luftqualität in Schulräumen - flexible und nachhaltige Lösungen Kombinieren von Ventilation/Lüftung mit HEPA-Filterung reduziert Aerosole am effizientesten und verbessert die Energiebilanz.

Wenn aber die verfügbaren technischen Möglichkeiten (mobile Luftreiniger, mechanische Lüftungen) in den Schulräumen weiterhin NICHT genutzt werden, hat das hochansteckende #SARSCoV2 mit seinen Immunfluchtvarianten leichtes Spiel.

Nach #XBB15, #JN1 und Co. bald auch bei uns: #XEC

17 3 1 0